Date: Thursday, March 25, 2021 at 10 AM PST
Online Breakout Session with Industry Council Members Horizon (formerly Viela-Bio), Genentech, and Alexion to discuss their FDA-approved treatments for NMOSD. This 90 minute event was hosted by GJCF Chief Medical Advisor Dr. Michael Yeaman.
Featured speakers include:
Maureen Mealy, Field Medical Affairs Director, Horizon
Tiffany Baerwaldt, Market Analysis & Strategy, Genentech
Yuriy Edwards, Medical Director, U.S. Medical Affairs, Neurology, Alexion
Maureen A. Mealy, PhD, has longstanding clinical and research expertise in rare immune-mediated diseases of the central nervous system, including neuromyelitis optica (NMO) and transverse myelitis (TM), having worked at Johns Hopkins for most of her career with Drs. Michael Levy, Carlos Pardo and Benjamin Greenberg. She acted as the Program Manager, Clinical Research Director, and Senior Nurse of the Johns Hopkins TM Center and NMO Clinic. Dr. Mealy has been involved in collaborative research investigations and data dissemination in over 40 peer-reviewed manuscripts. She joined the team at Viela Bio (now Horizon Therapeutics), a biotech company which shares in her passion for advancing the treatment of immune-mediated diseases including NMO by selectively targeting critical disease pathways. Prior to launch, she acted as the Medical Affairs Manager working on internal launch readiness activities before transitioning into the field for launch. She is deeply committed to sharing her clinical expertise in NMO with the team, and is also dedicated to patient, family and community engagement and education.
Tiffany Baerwaldt has been on the neuroscience team at Genentech for four years. Tiffany is dedicated to addressing the unique access needs of individuals with NMOSD, and leads initiatives to help people who need Genentech medicines, so they can focus on what matters most.
Yuriy Edwards, M.D., Ph.D., is Medical Director and U.S. Medical Lead for the NMOSD program at Alexion Pharmaceuticals. He has over 25 years of experience in medical affairs, direct patient care, neuroscience, and clinical research to advance the work on the exciting portfolio of therapies for patients with neurologic disorders. In his previous medical affairs roles, Yuriy was responsible for the development and implementation of medical strategy to ensure product launch readiness for late-stage clinical programs in various disease indications within the neurology therapeutic space
